Loading [Contrib]/a11y/accessibility-menu.js
JHEOR
  • Menu
  • Articles
    • Author Correction
    • Autoimmune Diseases
    • Cardiovascular Conditions
    • Commentary
    • Dermatological Diseases
    • Endocrine Diseases
    • Gastrointestinal Conditions
    • General Indications
    • Hematology
    • Hereditary Genetic Disorders
    • Infectious Diseases
    • Methodology and Healthcare Policy
    • Nephrologic/Hepatologic Conditions
    • Neurological Diseases
    • Oncology
    • Ophthalmology
    • Other Conditions
    • Psychological Conditions
    • Respiratory Diseases
    • Trauma Induced Conditions
    • Urological/Gynecological Diseases
    • All
  • For Authors
  • Editorial Board
  • About
  • Issues
  • Blog
  • Journal Policies
  • For Reviewers
  • search

    Sorry, something went wrong. Please try your search again.
    ×

    • Articles
    • Blog posts

RSS Feed

Enter the URL below into your favorite RSS reader.

https://jheor.org/feed
×
Infectious Diseases
Vol. 1, Issue 1, 2013 June 05, 2013 EDT

Economic Evaluation of Boceprevir for the Treatment of Patients with Genotype 1 Chronic Hepatitis C Virus Infection in Hungary

Raymond Odhiambo , Jagpreet Chhatwal , Shannon Allen Ferrante , Antoine El Khoury , Elamin Elbasha ,
  • ribavirin
  • peginterferon
  • markov model
  • cost-effectiveness
  • boceprevir
  • chronic hepatitis c
ccby-4.0 • https://doi.org/10.36469/9854
JHEOR
1.
Odhiambo R, Chhatwal J, Ferrante SA, El Khoury A, Elbasha E. Economic Evaluation of Boceprevir for the Treatment of Patients with Genotype 1 Chronic Hepatitis C Virus Infection in Hungary. JHEOR. 2013;1(1):62-82. doi:10.36469/9854
Save article as...▾
  • PDF
  • XML
  • Citation (BibTeX)
Powered by Scholastica, the modern academic journal management system